SHOULD WE REDUCE THE DOSE OF BIOLOGICAL THERAPY TO ALL PATIENTS WITH INFLAMMATORY ARTHRITIS ACHIEVING SUSTAINED THERAPEUTIC GOAL?

Gonzalez-Alvaro, I.Sanchez-Piedra, C.Almodovar, R.Bachiller, J.Balsa, A.Blasco, A. J.Caliz, R.Candelas, G.Fernandez-Carballido, C.Garcia-Aparicio, A.Garcia-Magallon, B.Garcia-Vicuna, R.Gomez-Centeno, A.Ortiz, A. M.Sanmarti, R.Sanz, J.Tejera, B.Notario, I.Soto, M. J.Plasencia, C.Hernandez, V.Espinosa, M.Ramos, C.Lazaro, P.2025-01-072025-01-072017-06-010003-4967https://hdl.handle.net/10668/26292enSHOULD WE REDUCE THE DOSE OF BIOLOGICAL THERAPY TO ALL PATIENTS WITH INFLAMMATORY ARTHRITIS ACHIEVING SUSTAINED THERAPEUTIC GOAL?conference outputopen access10.1136/annrheumdis-2017-eular.38361468-2060https://ard.bmj.com/content/annrheumdis/76/Suppl_2/452.1.full.pdf413181401333